

A novel digitalMLPA assay for comprehensive copy number variant detection in genes associated with cardiac disorders

Beatriz Alves, Nga Jien Chen, Santiago Castanedo Fontanillas, Jonas de Groot, Jan Schouten, Paul van Vught

MRC Holland, Amsterdam, the Netherlands

EP07.008

Introduction

Cardiac disorders are a major cause of mortality worldwide and are often driven by genetic alterations, including germline copy number variants (CNVs). Molecular genetic testing has evolved from single-gene assays to Next-Generation Sequencing (NGS)-based approaches. However, accurate CNV detection using these methods remains challenging and often requires complex bioinformatics analysis.

To address this limitation, we are developing **NXtec D011 Cardiac Panel**. This digitalMLPA assay detects CNVs across more than 60 genes and genomic regions associated with cardiac disorders, including cardiomyopathies, arrhythmia syndromes, familial hypercholesterolemia, and syndromic congenital heart disease.

digitalMLPA is a multiplex PCR-based technology that enables comprehensive CNV analysis through the simultaneous hybridisation of hundreds of probes, coupled with the high coverage of NGS. NXtec D011 Cardiac Panel contains over 900 target probes covering the genes and genomic regions outlined in **Table 1**.

Table 1. Genes and regions targeted by NXtec D011 Cardiac Panel.

Genes	ACTC1	ACTN2	ALPK3	APOB	BAG3	CACNA1C	CALM1
CALM2	CALM3	CASQ2	CHD7	CSRP3	DES	DSC2	DSG2
DSP	ELN	ETS1	FHL1	FHOD3	FLNC	GLA	JAG1
JPH2	JUP	KCNE1	KCNE2	KCNH2	KCNJ2	KCNJ5	KCNQ1
LAMP2	LDLR	LMNA	MYBPC3	MYH7	MYL2	MYL3	NEXN
PCSK9	PKP2	PLN	PRKAG2	PTPN11	RAFI	RBM20	RIT1
RYR2	SCN5A	TBX5	TECRL	TMEM43	TNNC1	TNNI3	TNNT2
TPM1	TRDN	TTN	TTR	VCL	Regions	1p36	22q11

Materials and Methods

The performance of NXtec D011 Cardiac Panel was evaluated by testing 39 DNA samples harbouring a diverse range of previously characterised CNVs that together cover 47 genes/regions targeted by this assay. The sample set consisted of cell line-derived DNA samples obtained from the Coriell Institute and externally provided DNA samples, for which independently determined genotype information was available.

Reactions were performed according to the digitalMLPA NXtec Protocol (MRC Holland), using ~40 ng of purified genomic DNA (**Figure 1**). digitalMLPA-derived PCR amplicons were pooled and sequenced on a NextSeq 1000 Sequencing System (Illumina). The resulting FASTQ files were analysed using Coffalyser digitalMLPA for CNV calling. All test samples were normalised against dedicated reference samples of the same sex to obtain the final probe ratios.




Figure 1. Schematic overview of the digitalMLPA workflow. DNA is denatured and the left and right probe oligonucleotides hybridise to their adjacent target sequences. The hybridised oligonucleotides are then ligated and exponentially amplified by PCR. The resulting products are sequenced on an Illumina platform and analysed using Coffalyser digitalMLPA software.

Conclusions

digitalMLPA assay NXtec D011 Cardiac Panel is a promising tool for reliable identification of CNVs in a wide range of genes and chromosomal regions associated with cardiac disorders:

- Simultaneous analysis of 62 target genes/regions in one single reaction, reducing the number of individual tests per sample.
- Accurate detection of CNVs from whole gene to single-exon level.
- Simple protocol and user-friendly analysis software.

Results

The digitalMLPA assay accurately detected all known CNVs across the sample set tested, except for one sample (**Figure 3**). The observed CNVs included both intragenic and whole gene deletions and duplications affecting 45 genes, as well as partial deletions and duplications of chromosomal regions 1p36 and 22q11 (**Figure 2**).




Figure 2. CNVs detected with NXtec D011 Cardiac Panel. Heatmap of probe ratios obtained using Coffalyser digitalMLPA, indicating the copy number (CN) status of a subset of genes targeted by D011 across 39 samples. Probe ratios are ordered per gene, by chromosomal position. Note: for sample NA10074 (male), a ratio of ~2 for *GLA*, *LAMP2* and *FHL1* corresponds to CN=2, not CN=4 as indicated by the colour scale, as these probes target a single copy on the X-chromosome but are normalised against autosomal reference probes.

A heterozygous duplication involving exon 47 of *CACNA1C* was identified in sample NA03435 (**Figure 3**), representing a smaller aberration than the previously reported duplication spanning exons 38-47. The discordance between these findings requires additional investigation.





Figure 3. Probe ratios for sample NA03435 carrying a *CACNA1C* exon 47 duplication. Each datapoint represents one probe. The y-axis indicates the probe ratio, which is normalised to the reference samples. The x-axis indicates the *CACNA1C* exon/intron targeted by one probe of D011. A ratio of 0.80-1.20 corresponds to CN=2, while a ratio of 1.30-1.65 corresponds to CN=3.

For further information please contact
Beatriz Alves at b.alves@mrcholland.com

Interested in testing this assay
with your samples?

Scan the QR code to register and receive
the latest news



Download this poster here:

